WuXi PharmaTech Rebounds; Prepares For A Surge In China Biologics
This article was originally published in PharmAsia News
Executive Summary
WuXi PharmaTech founder Ge Li has plenty of reasons to feel good these days, despite a widely publicized failed merger with Charles River Laboratories. The largest Chinese pharmaceutical contract research organization not only posted record earnings for the third quarter, it also raised guidance for the full year